THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
-Pharmacy issues related to H.R 6395/S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| GARY J KLINE | — |
Health Issues HCR
-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800 / H.R. 925 the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). -Issues related to H.R. 6810, the Health Care Protection Act, and H.R. 6514, the Worker Health Coverage Protection Act, and S. 4329, the Continuous Health Coverage for Workers Act. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. -Issues related to H.R. 6561/S. 4440 - Improving Social Determinants of Health Act of 2020 and H.R. 4004/ S. 2986, the Social Determinants Accelerator Act of 2019. -Issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act. -Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| JOE DUNN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
| DAVID SCHWARTZ | — |
Medicare/Medicaid MMM
-Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Policies that impact public programs payments for high cost drugs including gene therapies. -H.R.7659/S. 4840, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. -Issues related to prior authorization and utilization management, H.R. 3107, the Improving Seniors' Timely Access to Care Act of 2019. -Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL CANINO KALETA | — |
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| JOE DUNN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
Pharmacy PHA
-Pharmacy issues related to S. 1895, the Lower Health Care Costs Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| BRENDAN DEVINE | — |
| JOE DUNN | — |
| KRISTIN JULASON DAMATO | — |
| GARY J KLINE | — |
| COURTNEY LAWRENCE | — |
Affiliated organisations
| Organisation | Location |
|---|---|
| EXPRESS SCRIPTS, INC. | St. Louis, MO, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.